Arvinas (NASDAQ:ARVN) (NASDAQ: ARVN) is a biopharmaceutical company pioneering targeted protein degradation as a novel therapeutic approach. Founded in 2013 by Yale University Professor Craig Crews and Genentech veteran Mark L. Chrisler, Arvinas leverages its proprietary PROTAC® (PROteolysis TArgeting Chimera) platform to design small molecules that selectively degrade disease-causing proteins. By harnessing the body’s natural protein disposal system, the company aims to address a broad range of conditions, including oncology, neurodegeneration, and autoimmune diseases, where traditional inhibition strategies have proven challenging.
Arvinas’s lead clinical programs focus on hormone-driven cancers. ARV-110, an orally administered androgen receptor degrader, and ARV-471, an estrogen receptor degrader, are being evaluated in patients with advanced prostate and breast cancers, respectively. Both candidates have received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration, underscoring their potential to meet significant unmet medical needs. In preclinical studies, the PROTAC platform has demonstrated the ability to target proteins previously considered “undruggable,” expanding therapeutic possibilities across multiple disease areas.
To accelerate development and broaden the impact of its platform, Arvinas has forged strategic collaborations with major pharmaceutical companies, including Pfizer and Roche. These partnerships enable the joint exploration of novel targets and the co-development of degraders in oncology, immunology, and neurodegenerative disorders. Arvinas also maintains a robust pipeline of proprietary programs, supported by a deep intellectual property portfolio and a strong track record of innovation in protein degradation science.
Headquartered in New Haven, Connecticut, Arvinas conducts research, development, and clinical operations across the United States and Europe. The company’s leadership team comprises seasoned executives with extensive backgrounds in drug discovery, clinical development, and regulatory affairs. Under this experienced management, Arvinas remains committed to transforming the treatment landscape by advancing its PROTAC technology from concept to clinic and, ultimately, to patients worldwide.
